港股異動 | 中國飛鶴大漲超7%創新高 港股通持倉比例穩增
格隆匯4月15日丨中國飛鶴(6186.HK)現大漲7.16%,報14.36港元盤中創新高,暫成交3.2億港元,最新總市值1282.8億港元。公司股價自上市以來波幅上漲,陸續創出新高。近期中國飛鶴港股通持股佔比亦有明顯上升之勢,據格隆匯APP顯示,自3月以來港股持倉比例從不足1%升至3.51%。此外,當下海外正處於疫情暴發期,各國進入緊急狀態,隨之而來的是國內進口奶粉缺貨、斷供現象嚴重。市場人士認為,作為國內知名乳業品牌,短期公司將持續受益,疊加政策持續支持國內乳企,未來國內乳企品牌建設和規模效應都會更強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.